ホーム>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>20-HETE

20-HETE (Synonyms: 20-hydroxy Arachidonic Acid, 20-Hydroxyeicosatetraenoic Acid)

カタログ番号GC35075

MaxSpec®の同一性、純度、安定性、濃度仕様を満たすことが保証された量的分析基準

Products are for research use only. Not for human use. We do not sell to patients.

20-HETE 化学構造

Cas No.: 79551-86-3

サイズ 価格 在庫数 個数
25µg
$220.00
在庫あり
50µg
$419.00
在庫あり
100µg
$792.00
在庫あり
500µg
$3,295.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description of 20-HETE

20-HETE(20-hydroxy Arachidonic Acid) is a potent vasoconstrictor produced in vascular smooth muscle (VSM) cells. It depolarizes VSM by blocking the open-state probability of Ca2+-activated K+-channels.IC50 Value:Target: 20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450-derived arachidonic acid metabolite that has been shown to increase smooth muscle contractions and proliferation, stimulate endothelial dysfunction and activation and promote hypertension. in vitro: Addition of 20-HETE to the bath (1-100 nM), reduced the frequency of opening of the large-conductance Ca(2+)-activated K+ channel recorded using cell-attached patches on VSM [1]. In kidney, 20-HETE induces diuresis by inhibiting Na+-K+-ATPase in proximal tubules and Na+/K+/Cl+ cotransporter in the thick ascending limb of Henle's loop [2].in vivo: In Cyp4a14(-/-) mice, which display androgen-driven and 20-HETE-dependent hypertension, treatment with20-HETE antagonist abolished remodeling of renal resistance arteries measured as media thickness (24±1 vs. 15±1μm) and M/L (0.29±0.03 vs. 0.17±0.01) [4]. The transgenic mice had overexpressed hepatic CYP4F2, high hepatic 20-HETE and fasting plasma glucose levels but normal insulin level. The GP activity was increased and the cAMP/PKA-PhK-GP pathway was activated in the transgenic mice compared with wild-type mice [5]. Clinical trial: Mechanisms of Response to Diesel Exhaust in Subjects With Asthma. Phase not specified Human Endogenous Metabolite

[1]. Zou AP, Fleming JT, Falck JR, 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am J Physiol. 1996 Jan;270(1 Pt 2):R228-37. [2]. Schwartzman M, Ferreri NR, Carroll MA, Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature. 1985 Apr 18-24;314(6012):620-2. [3]. Ding Y, Wu CC, Garcia V, 20-HETE INDUCES REMODELING OF RENAL RESISTANCE ARTERIES INDEPENDENT OF BLOOD PRESSURE ELEVATION IN HYPERTENSION. Am J Physiol Renal Physiol. 2013 Jul 3. [Epub ahead of print] [4]. Lai G, Wu J, Liu X, 20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway. Mol Endocrinol. 2012 Nov;26(11):1907-16.

Chemical Properties of 20-HETE

Cas No. 79551-86-3 SDF
同義語 20-hydroxy Arachidonic Acid, 20-Hydroxyeicosatetraenoic Acid
Canonical SMILES O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCO
Formula C20H32O3 M.Wt 320.47
溶解度 0.1 M Na2CO3: 2 mg/ml ;DMF: Miscible ;DMSO: Miscible;Ethanol: Miscible;PBS pH 7.2: 0.8 mg/ml Storage Store at -20°C, protect from light
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of 20-HETE

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 3.1204 mL 15.6021 mL 31.2042 mL
5 mM 0.6241 mL 3.1204 mL 6.2408 mL
10 mM 0.312 mL 1.5602 mL 3.1204 mL
  • モルアリティ計算機

  • 希釈計算機

  • Molecular Weight Calculator

質量
=
濃度
x
容積
x
MW*
 
 
 
**ストックソリューションを準備する際には、常にバイアルラベルおよび MSDS/CoA(オンラインで利用可能)で掲載された製品のロット固有分子量を使用してください。

計算

In vivo Formulation Calculator (Clear solution) of 20-HETE

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Quality Control

レビュー

Review for 20-HETE

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 20-HETE

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.